GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » Median PS Value

DICE Therapeutics (DICE Therapeutics) Median PS Value : $0.00 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. DICE Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0. DICE Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-24), DICE Therapeutics's share price is $47.55. DICE Therapeutics's Median PS Value is $0.00. Therefore, DICE Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for DICE Therapeutics's Median PS Value or its related term are showing as below:

DICE's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

DICE Therapeutics Median PS Value Historical Data

The historical data trend for DICE Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DICE Therapeutics Median PS Value Chart

DICE Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Median PS Value
- - - -

DICE Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DICE Therapeutics's Median PS Value

For the Biotechnology subindustry, DICE Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DICE Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DICE Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where DICE Therapeutics's Price-to-Median-PS-Value falls into.



DICE Therapeutics Median PS Value Calculation

DICE Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
DICE Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DICE Therapeutics  (NAS:DICE) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

DICE Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=47.55/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DICE Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


DICE Therapeutics (DICE Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Executives
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen officer: CSO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson officer: CFO & CBO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy officer: CMO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice director, officer: CEO 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi director NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902